Q1 2022 Mediwound Ltd Earnings Call Transcript
Good day, and welcome to the MediWound First Quarter 2022 Financial Results and Presentation of the EscharEx Phase II clinical trial results conference call. (Operator Instructions)
At this time, I would like to turn the conference over to Monique Kosse of LifeSci Advisors. Please go ahead.
Thank you, operator, and welcome, everyone. Earlier today, MediWound issued a press release, announcing its first quarter 2022 financial results and provided a corporate update. We will be reviewing those results with the management team in addition to hearing from 2 KOLs on the results of the EscharEx U.S. Phase II trial, which were announced in a press release issued on May 12, 2022. You may access both releases on the company's website under the Investors tab.
With us today from management are Sharon Malka, Chief Executive Officer of MediWound; Ofer Gonen, Board member; and Boaz Gur-Lavie, Chief Financial Officer. Also joining us are Professor Lior Rosenberg, Chief Medical Officer; and Dr. Cyaandi Dove from
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |